Evidence-Based Care Pathway for Cellulitis Improves Process, Clinical, and Cost Outcomes
Evidence-Based Care Pathway for Cellulitis Improves Process, Clinical, and Cost Outcomes
复制标题
DOI:
10.1002/jhm.2433
复制
发表时间:
2015-12-01
影响因子:
2.6
通讯作者:
Kawamoto, Kensaku
中科院分区:
文献类型:
--
作者:
Yarbrough, Peter M.;Kukhareva, Polina V.;Kawamoto, Kensaku
BACKGROUND: Cellulitis is a common infection with wide variation of clinical care.OBJECTIVE: To implement an evidence-based care pathway and evaluate changes in process metrics, clinical outcomes, and cost for cellulitis.DESIGN: A retrospective observational pre-/postintervention study was performed.SETTING: University of Utah Health Care, a 500-bed academic medical center in Salt Lake City, Utah.PATIENTS: All patients 18 years or older admitted to the emergency department observation unit or hospital with a primary diagnosis of cellulitis.INTERVENTION: Development of an evidence-based care pathway for cellulitis embedded into the electronic medical record with education for all emergency and internal medicine physicians.MEASUREMENTS: Primary outcome of broad-spectrum antibiotic use. Secondary outcomes of computed tomography/magnetic resonance imaging orders, length of stay (LOS), 30-day readmission, and pharmacy, lab, imaging, and total facility costs.RESULTS: A total of 677 visits occurred, including 370 visits where order sets were used. Among all patients, there was a 59% decrease in the odds of ordering broad-spectrum antibiotics (P < 0.001), 23% decrease in pharmacy cost (P = 0.002), and 13% decrease in total facility cost (P = 0.006). Compared to patients for whom order sets were not used, patients for whom order sets were used had a 75%, 13%, and 25% greater decrease in the odds of ordering broad-spectrum antibiotics (P < 0.001), clinical LOS (P = 0.041), and pharmacy costs (P = 0.074), respectively.CONCLUSION: The evidence-based care pathway for cellulitis improved care at an academic medical center by reducing broad-spectrum antibiotic use, pharmacy costs, and total facility costs without an adverse change in LOS or 30-day readmissions. (C) 2015 Society of Hospital Medicine